WHO takes great pains not to embarrass individual countries for how well or poorly they "measure up," and this low-key approach ends up being a "core problem," Fineberg says. Although the idea of WHO helping in efforts to assess a country's capacity to deal with emerging infectious diseases "makes sense, national governments don't like it," Fukuda adds, noting that only about 20% of the countries have the appropriate capacity. "WHO is well-positioned to help with quality assessments, but we haven't found the right way to achieve the necessary political balance."
Another looming issue is how best to deal with the Convention on Biological Diversity (CBD), an international agreement from 1992 that was never intended to deal with public health issues. Nonetheless, some of its provi- The candidate antifungal drug efına-conazole is proving effective against toenail infections. The drug diffuses relatively freely through nails and binds less strongly to keratin than do other topically applied antifungal drugs, leaving it free to fıght the fungus, according to Keita Sugiura of Kaken Pharmaceutical of Kyoto, Japan, and his collaborators. "This study suggests that . . . low keratin affınity is needed for favorable penetration and retention of antifungal activity within the nail matrix," he says. Details appeared online 21 April 2014 and will be printed in the July 2014 Antimicrobial Agents and Chemotherapy.
Because topical antifungal drugs so often fail to cure this condition, physicians sometimes prescribe oral antifungal drugs such as terbinafıne and itraconazole for some of their patients with stubborn cases of onychomycosis. However, Sugiura points out, this approach "is limited" because such drugs can damage the liver or may interact with other drugs that patients are taking. Although topically applied antifungal drugs such as ciclopirox and amorolfıne have "a favorable safety profıle," he adds, "their cure rates are considerably lower." Sugiura and his collaborators tested human nails to fınd how well the drug diffuses through keratin-rich nails. Small 16 mm 2 squares from commercially available toenail material (who knew?) were mounted in Franz diffusion cells to measure how quickly several antifungal drugs pass through that material. Efınaconazole proved speediest, racing through the mounted nail squares within the fırst day, while ciclopirox took six days and amorolfıne remained undetected, they report.
Of several drugs tested, only efına-conazole inhibited fungal growth under nails in vitro, according to Sugiura.
He and his collaborators also tested the fungicidal activity of several topical antifungal products in a fluid keratin medium that is designed to "mimic the keratin-rich environment of the nail plate and nail bed." Without a solid matrix to block the drugs, efınaconazole proved slightly more potent at killing
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Shapes and Curves; Plus Revised View of Cell-Wall Growth
The shapes of microbial species are sometimes fanciful and can be important for their survival or may mask activities that are key to physiology. Recent examples include:
• Helicosporidium, a corkscrew-shaped intracellular parasite that feeds on juvenile insects, derived from algae but, unlike Plasmodium, the parasite responsible for malaria which also derived from algae, retained most of its genes except those explicitly needed for photosynthesis, according to the fungus than did amorolfıne and far more potent than ciclopirox, they note. "Efınaconazole is the fırst topical drug that has shown effıcacy for this persistent and common infection," says Boni Elewski of the University of Alabama, Birmingham, who last year led a pair of phase 3 clinical studies to evaluate this drug for treating onychomycosis, the formal name for chronic fungal infections of toenails. "I think this mechanism of action is indeed quite signifıcant, contributing to the relatively high mycologic cure rate in treating onychomycosis," says Elewskii.
The typical fungi responsible for onychomycosis include Trichophyton rubrum, T. mentagrophytes, Candida albicans, and nondermatophyte molds. The condition affects about 8% of the U.S. population, mainly adults, particularly those who are 60 years of age or older. While more a cosmetic than a frank health issue, onychomycosis can prove painful as well as being an eyesore, and may interfere with work that entails standing, food handling, modeling, or other interactions and relationships, Elewski points out. Oldfıeld at the University of Illinois, Urbana-Champaign, and his collaborators. Not only SQ109, but also a series of analogues inhibit the growth of a range of microorganisms, acting at various molecular targets-leading to "very low rates of spontaneous drug resistance," they report. "There's an urgent need for new drugs that are resistance-resistant, and drugs that hit multiple targets will reduce resistance," Oldfıeld adds. Details appeared February 25, 2014 in the Journal of Medicinal Chemistry (doi:10.1021/jm500131s).
SQ109 is a 1,2-diamine that is related to ethambutol, a widely used drug that is bacteriostatic against M. tuberculosis, blocking cell-wall production. Sequella, Inc. in Rockville, Md., a company focused on TB, began developing SQ109 in 2000, then in partnership with researchers at the National Institutes of Health (NIH) in nearby Bethesda, Md. Several years ago, members of the NIH group and their collaborators reported that SQ109 "interferes with the assembly of mycolic acids into the cell wall core of M. tuberculosis." They also concluded that the primary bacterial target for the drug was MmpL3, "a transporter of trehalose monomycolate," an ingredient of the cell wall in M. tuberculosis.
That seeming clarity for how SQ109 Triphosphate versions of those unnatural base pairs, designated d5SICS and dNaM, are brought into the E. coli bacterial cells via an algal transporter protein, and the DNA replication machinery of those cells "uses them to accurately replicate a plasmid," they report. The bacterial DNA repair apparatus leaves the altered plasmids alone, and the addition of the synthetic base pairs, which are not being translated into novel amino acids, does not appear to slow down the growth of the altered cells. Their next step in this research, Romesberg and his collaborators say, "will be to demonstrate the in-cell transcription of the new, expanded-alphabet DNA into the RNA that feeds the protein-making machinery of cells." Details appeared May 7, 2014 in Nature (doi: 10.1038/nature13314).
Fungal infections of toenails are particularly difficult to treat, chiefly because it is difficult to get antifungals to penetrate the nail. A new topical antifungal, efinaconazole, shows good penetration into infected nails and may be a breakthrough for treating infections that previously could only be treated with orally administered drugs. (Image © iStockphoto/4kodiak.)
